Chessboard

The first move has been made – now we are waiting for answers

After months of speculation, Trump has now moved his first pawn. On one side of the board, he sits with...

Krönika
yesterday 12:04

Saniona's new CFO: "More deals are definitely on the horizon"

Saniona has appointed Johnny Stilou as its new Chief Financial Officer. With a career spanning over 25 years...

Intervjuer
14th of May 2025

Hansa Biopharma appoints new Chief Operating Officer

Hansa Biopharma has appointed Maria Törnsén as Chief Operating Officer and Head of the US operations starting May 19. She will...

Notis
13th of May 2025

PharmaLundensis wants to postpone repayment

PharmaLundensis plans to negotiate an extended repayment period for a remaining convertible debt of approximately SEK 3,2 million, as the company...

Notis
13th of May 2025
Roche may reconsider $50 billion investment in the US

Roche may reconsider $50 billion investment in the US

Swiss pharmaceutical giant Roche is considering reevaluating its promise to invest $50 billion in the United States. The reason is...

Featured
Nyheter
13th of May 2025
Biosergen taps antifungal expert as board member

Biosergen strengthens the board with an expert in anti-infective drugs

Biosergen, a biotechnology company focused on developing treatments for life-threatening fungal infections, has nominated Dr. Marco Taglietti, MD, for...

Featured
Nyheter
12th of May 2025
Trump wants to cut drug prices by up to 80 percent

Trump wants to cut drug prices by up to 80 percent

President Donald Trump intends to sign an executive order aimed at dramatically lowering drug prices in the United States by...

Featured
Nyheter
12th of May 2025
EQL sets new high goals

EQL Pharma sets new high goals

Lund-based EQL Pharma concludes its five-year plan with impressive growth for the broken financial year 2024/2025. With a historic acquisition...

Nyheter
8th of May 2025

Strong growth for Alvotech – focus on product launches

Icelandic Alvotech reports explosive sales growth of 260 percent for the first quarter of 2025 and raises its full-year forecast after acquisitions and...

Nyheter
8th of May 2025
Novo Nordisk lowers forecast

Novo Nordisk lowers forecast – struggling with compounding

Novo Nordisk reports sales growth of 18 percent at constant exchange rates for the first quarter of 2025. At the same time, the company lowers its full-year forecast...

Nyheter
7th of May 2025
Gene therapy company backs down on new FDA appointment

Gene therapy company falls after new FDA appointment

Vinay Prasad has been named the new director of the FDA's Center for Biologics Evaluation and Research, causing concern among...

Nyheter
7th of May 2025

Europe is under pressure to raise its drug prices

When AstraZeneca CEO Pascal Soriot presented this year's Q1 report, he once again took the opportunity to warn that Europe's low...

Krönika
5th of May 2025